Published On:
Tue, Apr 28th, 2015
Tamir Capital soars after court ruling against Teva
Tamir Capital is invested in Proneuron, which successfully sued Teva for abuse of a license for its product.
Shares in Tamir Capital are soaring on lively volumes, following a Tel Aviv District Court ruling that Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) infringed the terms of a license from Proneuron Biotechnologies, and that the intellectual property rights should be restored to Proneuron immediately. Teva was also ordered to pay costs of about $100, 000.
The judge found that “Teva made a mistaken professional decision and embarked on an efficacy trial that was not well planned, since it ought to have given greater weight to the pre-clinical findings and to have examined their significance further before starting a clinical trial.”… [READ MORE]
Published by Globes [online], Israel business news – www.globes-online.com
Read more about: Asia, Business/Finance, Health/Medical/Pharmaceuticals, Law/Crime, Middle East, Pharmaceutical Industry, Pharmaceutical sciences, Proneuron Biotechnologies, Science and technology in Israel, Tamir Capital, Tel Aviv District Court, Tel Aviv stock exchange, Teva Pharmaceutical Industries, Teva Pharmaceutical Industries Ltd.(NYSE: TEVA; TASE: TEVA)